Marina A. Chernyatina

Marina A. Chernyatina

Auto-generated profile, based on publicly available information

Marina A. Chernyatina

Kursk State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2024 in Russian Journal of Cardiology and Cardiovascular Surgery
Verified
Journal Article
Closed access
VMV.P. Mikhin
V.P. Mikhin
NKN.L. Kostina
N.L. Kostina
TNT.A. Nikolenko
T.A. Nikolenko
VSV.V. Savelyeva
V.V. Savelyeva
MCM.A. Chernyatina
M.A. Chernyatina
A review of the literature is devoted to the effects of the ethylmethylhydroxypyridine succinate (mexidol) in patients with arterial hypertension. The analysis of 44 sources of Russian and foreign literature showed more effective achievement of the target values of blood pressure, prevention of severe complications in hypertensive crises in patients with mexidol therapy. The evidence of the positive effect of cytoprotective therapy on the condition of the left ventricle and vascular wall is considered. The results of large-scale studies demonstrating the effective correction of cognitive dysfunction of the brain using mexidol are presented. The role of the drug in stabilizing of biochemical processes, including lipid peroxidation, glucose and cholesterol metabolism, which determines the pleiotropic effects of mexidol in patients with hypertension, is emphasized.

1 January 2023 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
VMVadim P. Mikhin
Vadim P. Mikhin
АГАнна Игоревна Гиндлер
Анна Игоревна Гиндлер
НЗНаталья Викторовна Заикина
Наталья Викторовна Заикина
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
ТНТамара Александровна Николенко
Тамара Александровна Николенко
MCMarina A. Chernyatina
Marina A. Chernyatina
Objective: to conduct a comparative assessment of the parameters of heart rhythm and conduction in patients with Covid-19 with acute ST-segment elevation myocardial infarction (STEMI) in the hospital and post-hospital treatment periods. Materials and methods. The study included 140 patients with STEMI, stratified into 2 groups: I - the main (52 people) patients with STEMI who had COVID-19 for 1.5-6 months before the development of acute coronary syndrome (ACS), II - the comparison group (88 people) with STEMI without COVID-19 in the anamnesis. All patients underwent percutaneous coronary intervention with stenting of a single infarct-related artery in the first 24 hours. Daily ECG monitoring was performed with an assessment of traditional heart rate and conduction parameters for 2-3 days, 9-11 days and after 6 months from the moment of the accident. Results. In the main group, in contrast to the control group, a shortening of the QT interval (7.7% vs. 0.0%), ventricular extrasystole (VES) of Lown grade IV A (25.0% vs. 7.9%) was more often recorded on 2-3 days. Supraventricular extrasystole (SVE; 92.0% vs. 65.4%), sinus arrhythmia (37.5% vs. 0.0%), supraventricular tachycardia (SVT; 7.9% vs. 0.0%) were more often recorded in group II on 2-3 days. During the hospital follow-up period, the retention of shortened QT (7.7% vs. 0.0%), predominance SVE (90.4% vs. 76.1%), sinus arrhythmia (48.1% vs. 29.5%), migration of the rhythm driver along the atria (15.3% vs. 0.0%), VES Lown grade IV A (9.6 % vs. 0.0%). In the control group, AV blockade of 1 deg. (15.9% vs. 3.8%), AV blockade of 2 deg. (4.5% vs. 0.0%), CA blockade (3.4% vs. 0.0%), QT prolongation (12.5% vs. 0.0%) were more often determined. By 6 months after STEMI, patients in the main group were more likely to have SVT (9.6% vs. 0.0%) and VES Lown grade IV A (7.6% vs. 0.0%). In the control group, AV blockade of 1 deg. (9.0% vs. 0.0%), CA blockade (3.4% vs. 0.0%) were registered. Conclusion. Patients with STEMI who had a history of COVID-19 and without COVID-19 had a multidirectional dynamics of heart rate and conduction parameters during the hospital and post-hospital follow-up periods. In patients who underwent COVID-19, there was a predominance of ventricular arrhythmias of high Lown gradations on 2-3 days of STEMI, an increase in supraventricular arrhythmias on days 9-11, an increase in supraventricular and ventricular arrhythmias of high Lown gradations and the absence of CA and AB disorders after 6 months. In the control group, there was a predominance of supraventricular and ventricular arrhythmias of low gradations according to Lown, a predominance of CA and AB conduction disorders on days 9-11 and 6 months after STEMI.

1 January 2022 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
VMVadim P. Mikhin
Vadim P. Mikhin
VVValeriya V. Vorotyntseva
Valeriya V. Vorotyntseva
ТНТамара Александровна Николенко
Тамара Александровна Николенко
VSValentina V. Savelyeva
Valentina V. Savelyeva
MCMarina A. Chernyatina
Marina A. Chernyatina
НГНиколай Ильич Громнацкий
Николай Ильич Громнацкий
Objective: to evaluate the features of changes in the content of metalloproteinase-12 (MMR-12) in blood serum in patients with arterial hypertension (AH) of high cardiovascular risk (SSR) against the background of therapy with atorvastatin (20 mg/day) or rosuvastatin (10 mg/day; 20 mg/day; 40 mg / day) as part of complex therapy. Materials and methods. The study included 140 patients with stage II hypertension, with partially controlled BP, the duration of the disease is 5-12 years, who, against the background of hypotensive therapy (enalapril 20-40 mg/ day, indapamide retard 1.5 mg, metoprolol 100-150 mg/day) received atorvastatin (Liprimar) 20 mg/day for 1 year, subsequently, it was replaced with rosuvastatin (Rosucard)10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of low-density lipoprotein cholesterol (LDL) and cholesterol (HC). Results. During atorvastatin therapy, the content of MMR-12 in each of the three groups did not change. In the group of patients taking rosuvastatin 10 mg / day, the content of MMP-12 did not change for 18 months In the group of patients taking rosuvastine 20 mg / day, a decrease in MMP-12 was observed only by 12 months of therapy - by 26.8%, by 18 months - by 30.4% (p<0.05) When taking rosuvastine 40 mg / day, a decrease in MMP-12 was observed by 24.1% by 6 months, by 12 months - by 35.3%, by 18 months - by 37.1% (p<0.05). Conclusion. In patients with hypertension with high SSR, rosuvastatin as part of a complex therapy had an ambiguous effect on the content of MMR-12 in the blood, the greatest decrease in the level of MMR-12 was registered when taking 40 mg / day of rosuvastatin.

1 January 2022 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
GPGladchenko Mikhail P.
Gladchenko Mikhail P.
ABArtyushkova Elena B.
Artyushkova Elena B.
FGFrolova Oxana G.
Frolova Oxana G.
MSMal Galina S.
Mal Galina S.
KVKhvostovoy Vladimir V.
Khvostovoy Vladimir V.
PRPuchak Irina R.
Puchak Irina R.
The objective of this work was to investigate in experiments on laboratory rats the possibility of reducing the cardiotoxicity of the anticancer drug Mitomycin C by mixing it with Mesogel before injection and using Mexicor® as a cardioprotective agent. Materials and methods. To carry out the study, 70 male Wistar rats were used. The body weight of laboratory animals at the beginning of the experimental study ranged from 180 to 220 grams. Intraperitoneal administration of Mitomycin C at a dose of 4 mg/kg once at the start of the study was used. When Mitomycin C was administered together with Mesogel, the drugs were combined under aseptic conditions before intraperitoneal administration, and Mesogel was administered at a volume of 10.7 ml/kg. The drug Mexicor® was administered in the form of intramuscular injections at a dose of 60 mg/kg per day for 14 days. Results. After intraperitoneal injection of the drug "Mitomycin C" at a dose of 4 mg / kg, a noticeable decrease in the contractility of the rat myocardium during exercise tests was observed only on the 14th day. The use of "Mitomycin C" mixed with "Mesogel" during intraperitoneal administration had a positive effect, but did not completely exclude the manifestation of the cardiotoxic effects of "Mitomycin C". The greatest efficiency was demonstrated in groups of animals that received "Mitomycin C" in a mixture with "Mesogel" together with the cytoprotective drug "Mexicor®". Conclusion. The combination of "Mitomycin C" immobilisation in "Mesogel" together with the cytoprotective drug "Mexicor®" was found to eliminate the cardiotoxic effects of "Mitomycin C" to the greatest extent.

26 September 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
VMV. P. Mikhin
V. P. Mikhin
OOO. A. Osipova
O. A. Osipova
AGA. I. Gindler
A. I. Gindler
ABA. S. Brizhaneva
A. S. Brizhaneva
NZN. V. Zaikina
N. V. Zaikina
MCM. A. Chernyatina
M. A. Chernyatina
Aim. To compare heart rate variability parameters in patients after a coronavirus disease 2019 (COVID-19) with acute ST elevation myocardial infarction (STEMI) during the inhospital and post-hospital periods. Material and methods. A total of 140 patients with STEMI were divided into 2 groups: I — patients with STEMI who had COVID-19 (n=52) in the period of 1,5-6 months before acute coronary syndrome, II — comparison group (n=88), which included patients with STEMI without prior COVID-19. All patients underwent infarct-related artery stenting within the first 24 hours from the onset. Heart rate variability (HRV) parameters were determined for all patients on days 2-3 and days 9-11 and 6 months after the hospitalization for STEMI. Results. Patients in group I showed more pronounced changes in HRV indicators on days 2-3 of STEMI: RMSSD (root square of successive RR intervals) by 21% (p=0,026), variations (Var) (the difference between the minimum and maximum RR intervals) by 33% (p=0,013), VLF (total very low-frequency HRV) by 7% (p=0,009) were higher, and HF (highfrequency HRV) by 40% (p=0,003), pNN50% (ratio of the number of consecutive RR interval pairs differing by >50 ms to the total number of RR intervals) by 66% (p=0,038) were lower than in the control group, respectively. On days 9-11 of the disease in patients with a history of STEMI and COVID-19, in contrast to the control group, there was a more pronounced increase in the SDNN (standard deviation of RR intervals) by 46% (p=0,005), VLF by 42% (p=0,031), whereas in the control group there were an increase of only 22% (p=0,004) and 11% (p=0,022), respectively. The HF value in the main group increased by 25% (p=0,007), while in the control group it decreased by 19% (p=0,030). Six months after STEMI in the main group, the RMSSD decreased by 19% (p=0,009), Var by 16% (p=0,041), VLF by 30% (p=0,025), LF (low-frequency component HRV) by 11% (p=0,005), while the control group these parameters decreased by 20% (p=0,006), 21% (p=0,001), 9% (p=0,011), and 7% (p=0,016), respectively. Conclusion. In patients with STEMI and prior COVID-19, the initial HRV values differ from similar HRV parameters in patients with STEMI without prior COVID-19. In the hospital and post-hospital periods, the changes of HRV in patients with and without COVID-19 are multidirectional as follows: pronounced sympathetic hyperactivity predominates, and slower recovery of HRV in patients after COVID-19 predominates.

1 January 2023 in Человек и его здоровье
Verified
Journal Article
Open access
PDF file
VMVadim P. Mikhin
Vadim P. Mikhin
АГАнна Игоревна Гиндлер
Анна Игоревна Гиндлер
НЗНаталья Викторовна Заикина
Наталья Викторовна Заикина
МЗМаргарита Павловна Заикина
Маргарита Павловна Заикина
ТНТамара Александровна Николенко
Тамара Александровна Николенко
АААнтон Михайлович Александров
Антон Михайлович Александров
Objective: to evaluate the features of central and intracardiac hemodynamics in patients with ST-segment elevation myocardial infarction (STEMI), who underwent COVID-19 during inpatient stay and 6 months after the development of STEMI. Materials and methods. 140 patients with STEMI were included in the study. The patients were randomized into 2 groups: I - main group - patients with STEMI who suffered COVID-19 (52 people) in the period from 1.5-6 months before the development of acute coronary syndrome (ACS), II - comparison group (88 people) which included patients with STEMI who did not have COVID-19 in the anamnesis. All patients underwent PCI with stenting of the infarct-related artery in the first 24 hours from the onset of ACS. The parameters of central and intracardiac hemodynamics in all patients were determined for 2-3 days (1st control point), 9-11 days (2nd control point), after 6 months (3rd control point) from the moment of hospitalization for STEMI. Results. In the patients of the main group of the study, more pronounced changes in the systolic-diastolic LV function were recorded on the 2-3 day of STEMI: LV EF by 8.5%, Sm by 7.2% and E' by 24.5% (p<0.05) were lower than in the control group, respectively, E/E' by 11.5% and WMSI by 21.8% (p<0.05) were higher than in the comparison group. On the 9th-11th day of the disease in patients with STEMI who underwent COVID-19, a slowdown in the recovery of the studied parameters was revealed: the LV EF value was lower than in the control group by 11%, Sm by 12% and E' by 20% (p<0.05), respectively, and the value of E/E' by 27% and WMSI by 25% (p<0.05) were higher than in the comparison group. 6 months after STEMI, there were no significant differences in Sm, E', E/E' values in the main and control groups, however, a lower LVEF and WMSI value was noted in comparison with the control group (p<0.05). Conclusion. Unidirectional positive dynamics of systolic-diastolic function parameters in hospital and post-hospital follow-up periods was observed in patients with STEMI, both those who had COVID-19 and without COVID-19 in the anamnesis. However, in patients who underwent COVID-19, there were more pronounced violations of LV systolic-diastolic function on 2-3 days and less pronounced, delayed positive dynamics of these parameters during the hospital and post-hospital treatment periods.